BiotechTube
Dermapharm

Dermapharm

DMP.F
Grünwald, Germany· Est. 1991

Dermapharm Holding SE is a Germany-based pharmaceutical group with a core focus on dermatology and other therapeutic areas such as cardiovascular, pain, and anti-infectives. The company operates through two main segments: 'Branded Pharmaceuticals and Other Healthcare Products' and 'Parallel Import Business'. Its strategy is built on a 'buy-and-build' approach, acquiring and integrating established pharmaceutical brands and companies to drive growth. Dermapharm is listed on the Frankfurt Stock Exchange and has achieved significant scale with a market valuation in the billions.

dermapharm.de

DMP.F · Stock Price

USD 41.70+2.20 (+5.57%)
Market Cap: $2.6B

Historical price data

AI Company Overview

Dermapharm Holding SE is a Germany-based pharmaceutical group with a core focus on dermatology and other therapeutic areas such as cardiovascular, pain, and anti-infectives. The company operates through two main segments: 'Branded Pharmaceuticals and Other Healthcare Products' and 'Parallel Import Business'. Its strategy is built on a 'buy-and-build' approach, acquiring and integrating established pharmaceutical brands and companies to drive growth. Dermapharm is listed on the Frankfurt Stock Exchange and has achieved significant scale with a market valuation in the billions.

DermatologyCardiovascularPainAnti-infectivesRheumatology

Technology Platform

Expertise in the development, formulation, and lifecycle management of established active pharmaceutical ingredients (APIs), with a focus on generics, branded generics, and biosimilars. Core capabilities include pharmaceutical formulation and vertically integrated manufacturing.

Funding History

1
IPOUndisclosedJul 7, 2017

Opportunities

The primary growth opportunities lie in the expanding European biosimilars market, driven by patent expiries of major biologics.
Further consolidation of the fragmented European specialty pharma market through strategic acquisitions presents another significant avenue for growth and margin enhancement.

Risk Factors

Key risks include sustained pricing pressure and margin erosion in the core generics business from European healthcare cost-containment policies.
Execution risk associated with the company's acquisition-led growth strategy and potential supply chain disruptions are also material challenges.

Competitive Landscape

Dermapharm competes with large global generics firms (e.g., Teva, Sandoz) and European specialty pharma peers (e.g., STADA, Recordati). Its differentiation is rooted in its strong German market focus, vertical integration, and proven expertise in dermatology and lifecycle management of established pharmaceuticals.